Alejo Rodríguez‐Vida

Author

Also Known As

A Rodriguez-Vida, A. Rodriguez-Vida, A. Rodríguez-Vida, A.M. Rodriguez-Vida, Albert Font, Alejo Rodriguez-Vida, Alejo Rodriguez‐Vida, Alejo Rodríguez-Vida, Alejo Rodríguez‐Vida, J.C. Villa-Guzmán

225

Publications

5.9K

Citations

H-Index

Concepts

All Affiliations

Hospital Del Mar Institut Català d'Oncologia Universitat Autònoma de Barcelona Queen Mary University of London Vall d'Hebron Hospital Universitari

About

Alejo Rodríguez‐Vida is an author at Hospital Del Mar specializing in medicine, cancer therapeutics, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	32	3.3K
2	Health Sciences	5	5	161
3	Immunology	5	5	145
4	Orthopaedics	3	3	116
5	Diagnostic Sciences	1	1	35

Alejo Rodríguez‐Vida

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida, Nature Medicine UrologyBiomarker AnalysisGenitourinary CancerMedicineCancer Treatment	2019	555
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer Elena Castro, Nuria Romero-Laorden, Ángela del Pozo, Journal of Clinical Oncology	2019	366
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone Diletta Bianchini, David Lorente, Alejo Rodríguez‐Vida, European Journal of Cancer Medicinal ChemistryUrologyMedicinePharmacologyPharmacotherapy	2013	209
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2017	175
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder Bernadett Szabados, Mark Kockx, Zoe J. Assaf, European Urology UrologyGenitourinary CancerMuscle-invasive Urothelial CancerMedicineCancer Treatment	2022	175
A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). Thomas Powles, Alejo Rodríguez‐Vida, Ignacio Durán, Journal of Clinical Oncology UrologySurgical OncologyTumoral PathologyPd-l1 InhibitorGenitourinary Cancer	2018	90
Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors Ali Raza Khaki, Ang Li, Leonidas Nikolaos Diamantopoulos, Cancer	2019	89
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Oncology Platinum-based TherapyUrologyGenitourinary CancerMedicineDocetaxel Versus Placebo	2019	83
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non–Muscle-Invasive Bladder Cancer Joaquim Bellmunt, Jaegil Kim, Brendan Reardon, Cancer Research	2020	73

Page 1